Screener
Bicara Therapeutics BCAX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 4,083 | 5,014 |
| Total other income | 4,083 | 5,014 |
| Net loss before income taxes | (56,159) | (36,774) |
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
| Net Loss per share, basic and diluted | $(0.93) | $(0.68) |
| Weighted-average number common shares outstanding, basic and diluted | 60,717,041 | 54,456,515 |
| Other comprehensive loss: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's income tax?
- Bicara Therapeutics (BCAX) reported income tax of $52K in Q1 2026.
- How has Bicara Therapeutics's income tax changed year-over-year?
- Bicara Therapeutics's income tax decreased by 27.8% year-over-year, from $72K to $52K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Bicara Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude